Resumen
Muchos de los pacientes con migraña requieren un tratamiento preventivo, para disminuir la frecuencia, la intensidad y la duración de las crisis, mejorar la calidad de vida, y mejorar la respuesta a los tratamientos abortivos para los ataques. El tratamiento puede ser farmacológico, no farmacológico, o la combinación de ambos.
En este artículo se revisan las indicaciones para la prevención de la migraña, los diferentes medicamentos que se utilizan, sus mecanismos de acción, efectos adversos y limitaciones terapéuticas, y las precauciones que se deben tener al combinar la terapia abortiva y preventivo de la migraña
Citas
- Anthony M, Hinterberger H, Lance JW. Plasma serotonin in migraine and stress. Arch Neurol 1967;16:544-552.
- Aoki KR. Evidence of antinociceptive activity of botulinum toxin type A in pain management. Headache 2003;43(suppl 1):S9-S15.
- Arts WFM, Scholte HR, Boggard JM, et al. NADH- CoQ reductase deficient myopathy: successful treatment with riboflavin. Lancet 1983;2:581-582.
- Aurora SK, Ahman BK, Alsayed F, et al. Cortical stimulation silent period is shown in migraine with aura. Neurology 1998;50[Suppl 4]:351-352.
- Ayatta C, Jin H, Kudd C, Dalkara T, Moskowitz MA. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 2006;59:652-661. toxin type A for the prophylaxis of chronic daily headache subgroup analysis of patients not receiving the prophylactic medication; a randomized double blind placebo controlled study. Headache 2005;45:315-324.
- Dolly O. Synaptic transmissions; inhibition of neurotransmitter release by botulinum toxin. Headache 2003;43(suppl 1):S16-S24.
- Durham PL, Cady R, Cady R. Regulation of calcitonin-gene-related-peptide secretion from trigeminal nerve cells by botulinum toxin type A; implications for migraine therapy. Headache 2004;44:35-43.
- Dvorkin GS, Aderman F, Carpenter S. Classical migraine, intractable epilepsy and multiple strokes: a syndrome related to mitochondrial encephalopathy. In: Anderman F, Lugaresi E, eds. Migraine and epilepsy. Boston: Butterworths, 1987:203-232.
- Eross EG, Dodick DW. The effects of botulinum toxin type A on disability in episodic and chronic migraine. Paper presented at the American Headache Society 44th Annual Scientific
- Barbiroli B, Montagna P, Cortelli P, et al. Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura. Neurology 1992;42:1209-1214.
- Barrientos N, Chana P. Efficacy and safety of botulinum toxin type A in the prophylactic treatment of migraine. Paper presented at the American Headache Society 44th Annual Scientific Meeting. Seattle WA; June 21-23, 2002.
- Binder WJ, Brin MF, Blitzer A, et al. Botulinum toxin type A for treatment of migraine headaches: an open-label study. Otolgolaryngol Head Neck Surg 2000;123:669-676.
- Blin O, Azulay J, Masson G, et al. Apomorphine-induced yawning in migraine patients: enhanced responsiveness. Clin Neuropharmacol 1991;14:91-95.
- Brandes JL, Saper JR, Diamond M, Couch JR, et al. Topiramate for migraine prevention. A randomized controlled trial. JAMA 2004;291:965-973.
- Brin ME, Swope DM, O’Brien C, et al. Botox for migraine: double blind, placebo-controlled, region-specific evaluation [abstract]. Cephalalgia 2000;20:421.
- Couch JR, Ziegler DK, Hassaneur R. Amitriptyline in the prophylaxis of migraine: effectiveness and relationship of antimigraine and antidepressant effects. Neurology 1976;26:121-127.
- Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin type A reduces formalin- induced pain. Pain 2004;107:125-133.
- Curran DA, Hinterberger H, Lance JW. Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m- methoxymandelic acid excretion in normal and migrainous subjects. Brain 1965;88:997-1010.
- Cutrer FM, Limmroth V, Ayata G, et al. Valproate reduces C-Fos expression in trigeminal nucleus caudalis (TNC) after noxious meningeal stimulation. Cephalalgia 1995;15[Suppl 14]:96.
- Cutrer FM, Moskowitz MA. Actions of valproate and neurosteroids in a model of trigeminal pain. Headache 1996;36:285.
- Dodick EW, Mauskop A, Elkind AH, deGryse R, Brin MF, Silberstein SD, Botox CDH study group. Botulinum Meeting. Seattle WA; June 21-23, 2002.
- Facchinetti F, Sances G, Borella P, et al. Magnesium prophylaxis of menstrual effects on intracellular magnesium. Headache 1991;31:298-310.
- Fisher CM. Late life migraine accompaniments, further experience. Stroke 1986;17:1033-1042.
- Girowell A, Kulisevsky J, Barbanog M, et al. A double- blind placebo controlled comparative trial of gabapentin and propranolol in patients with essential tremor. Neurology 1988;50:A71-A72.
- Golla FL, Winter AL. Analysis of cerebral responses to flicker in patients complaining of episodic headache. Electroencephalogr Clin Neurophysiol 1959;11:539-549.
- Gorson KG, Schott C, Rand WM, et al. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled double-blind, crossover trial. Neurology 1998;50:A103.
- Gray RN, Goslin RE, McCrory DC, Eberlein K, Tulsky J, Hasselslad V. Drug treatments for prevention of migraine headache prepared for the agency for healthcare policy and research. Contract No. 290-94-2025. Available from national technical information service accession no. 127953 (Technical Review 2-3) February 1999.
- Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine double-blind study versus placebo. Cephalalgia 1992;12:81-84.
- Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect on migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 1994;44:647-651.
- Joutel A, Bousser MG, Biousse V, et al. A gene for familial hemiplegia migraine maps to chromosome 19. Nat Genet 1993;5:40-45.
- Kaniecki RG. A comparative study of propranolol and divalproex sodium in the prophylaxis of migraine. Arch Neurol 1997;54:1141-1144.
- Kimball RW, Friedman AP, Vallejo E. Effect of serotonin in migraine patients. Neurology 1960;10:107-111.
- Klapper JA, Klapper A. Use of botulinum toxin in chronic daily headaches associated with migraine. Headache Q 1999;10:141-143.
- Klapper JA, Mathew NT, Klapper A, et al. Botulinum toxin type A (BTX-A) for the prophylaxis of chronic daily headache [abstract]. Cephalalgia 2000;20:292-293.
- Limmroth V, Lee WS, Cutrer FM, et al. Meningeal GABAA receptors located outside the blood brain barrier mediate sodium valproate blockade of neurogenic and substance P-induced inflammation: possible mechanisms in migraine. Cephalalgia 1995;15:102.
- Lipton RB, Gobel LH, Wilks K, Mauskop A. Efficacy of Petasites (an extract from Petasites rhizome) 50 and 75 mg for prophylaxis of migraine: results of a randomized double-blind, placebo-controlled study. Neurology 2002, 58 [Suppl 1] A472.
- Malick A, Burstein R. Peripheral and central sensitization during migraine. Funct Neurol 2000;15 (suppl 3):28-35.
- Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C. For the Botox CDH study group botulinum toxin type A (Botox) for the prophylactic treatment of chronic daily headache; a randomized, double blind, placebo controlled trial. Headache 2005;45: 293-307.
- Mathew NT, Kailasam J, Kaupp A, et al. “Disease modification” in chronic migraine with botulinum toxin type A: long-term experience. Paper presented at the American Headache Society 44th Annual Scientific Meeting. Seattle WA; June 21-23, 2002.
- Mathew NT, Kailasam J, Seifert T. Clinical recognition of allodynia in migraine. Neurology 2004;63:848-852.
- Mathew NT, Mullani N. Migraine with persistent visual aura measured by PET. Abstract Neurol 1998;50[Suppl 4]:A350-A351.
- Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001;41:119-128.
- Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Neurology 1995;52:281-286.
- Mathew NT, Schmitt TJ, Neto W, Jacobs D. Topiramate in migraine prevention: MIGR 001. Neurology 2003;60[Suppl 1]:A336.
- Mathew NT. Gabapentin in migraine prophylaxis.
Cephalalgia 1996;16:367.
- Mathew NT. Prophylaxis of migraine and mixed headaches. Headache 1981;20:105-109.
- Mauskop A, Altura BT, Cracco RQ, et al. Intravenous magnesium sulfate relieves migraine attacks in patients with low serum ionized magnesium levels: a pilot study. Clin Sci 1995;89:633-636.
- Mauskop A. Long-term use of botulinum toxin type A (Botox®) in the treatment of episodic and chronic migraine headaches. Paper presented at the American Headache Society 44th Annual Scientific Meeting. Seattle WA; June 21-23, 2002.
- Mosewich RK, Donat JR, DiMauro S, et al. The syndrome of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes presenting without stroke. Arch Neurol 1993;50:275-278.
- Nishikawa T, Scatton B. Inhibitory influence of GABA on central serotoninergic transmission: raphi nuclei as the neuroanatomical site of GABAergic inhibition of cerebral serotoninergic neurons. Brain Res 1985;341:331-391.
- Nyrke T, Kangasniemi P, Land AH. Difference of steady-state visual evoked potentials in classic and common migraine. Electroencephalogr Clin Neurophysiol 1989;73:285-294.
- Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996;87:543-552.
- Peatfield RC, Olesen J. Migraine: precipitating factors. In: Oleson J, Tfelt-Hansen P, Welch KMA, eds. The headaches. New York: Raven Press, 1993:243.
- Penn AMW, Lee JWK, Thuillier P, et al. MELAS syndrome with mitochondrial tRNALeulUURI mutation: correlation of clinical state, nerve conduction, and muscle31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology 1992;42:2147-52.
- Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the prophylaxis of migraine: a double-blind placebo controlled study. Cephalalgia 1996;16:436-440.
- Ramadan NM, Halvorson H, Vande-Linde A, et al. Low brain magnesium in migraine. Headache 1989;29:416-419.
- Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frisugurg B. Evidence-based guidelines of the pharmacological management for prevention of migraine for the primary care provider. http:www.Neurology.org 1999.
- Sandor PS, Diclemende L, Coppola G, et al. Co-enzyme Q10 for migraine prophylaxis: A randomized controlled trial. Cephalalgia 2003;23:577.
- Saper JR, Silberstein SD, Lake AE, et al. Double-blind trials of fluoxetine: chronic daily headache and migraine. Headache 1994;34:497-502.
- Schoenen J, Jacquy J, Lemaerts M. Effectiveness of high dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology 1998;50:466-469.
- Schoenen J, Maertens de Noordhout A. Contingent negative variation and efficacy of beta-blocking agents in migraine. Cephalalgia 1986;6:229-234.
- Schrader H, Stovner LI, Helde G, et al. Prophylactic treatment of migraine with angiotensin connecting enzyme inhibitor (lisinopril): Randomized placebo controlled crossover study. BMJ 2001;322:19-22.
- Silberstein S, Mathew N, Saper J, et al. Botulinum toxin type A as a migraine preventive treatment. Headache 2000;40:445-450.
- Silberstein SD, Neto W, Schmitt J, Jacobs D. For MIGR-001 Study Group. Topiramate in migraine prevention. Results of a large controlled trial. Arch Neurol 2004;61:490-495.
- Silberstein SD, Saper JR, Freitag F. Migraine diagnosis and treatment. In: Silberstein SD, Lipton RB, Dalessio DJ. eds. Wolffs headache and other head pain, 7th edition. New York: Oxford University Press, 2003:121-237.
- Silberstein SD, Stark SR, Lucas SM, Christie SM, deGryse RE, Turkel C. Botulinum toxin type A (Botox) for the prophylactic treatment of chronic daily headache; a randomized double blind placebo controlled trial. Mayo Clinic proceedings 2005;80:1126-1137.
- Silberstein SD. Transformed and chronic migraine. In; Goadsby P, Silberstein S, Dodick EW, eds. Chronic Daily Headache for Clinicians. Hamilton, Ontario; BC Decker Inc. 2005:21-56.
- Silberstein SO, et al. Topiramate in chronic migraine: A multicenter randomized placebo controlled trial - presented at the annual meeting of American Headache Society, 2006. Los Angeles, CA.
- Spira PJ, Beran RG. Australian gabapentin chronic daily headache group. Gabapentin in the prophylaxis of chronic daily headache: a randomized placebo controlled study. Neurology 2000;61:1753-1759.
- Steiner TJ, Ahmed F, Findley LJ, et al. S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study. Cephalalgia 1998;18:289-286.
- Tfelt-Hansen P, Welch KMA. Migraine: prioritizing prophylactic treatment. In: Olesen J. Tfelt-Hansen P, Welch KMA, eds. The headaches, 2nd Ed. Philadelphia: Lippincott Williams & Wilkins, 2000:499-505.
- Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with angiotensin II receptor blocker: A randomized controlled trial. JAMA 2003;289:65-69.
- Vogler BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: A systemic review. Cephalalgia 1998;18:421-435.
- Welch KMA, D’Andrea G, Tepley N, et al. The concept of migraine as a state of central neuronal hyperexcitability. Neurol Clin 1990;8:817-828.
- Welch KMA, Levine SR, D’Andrea G, et al. Preliminary observations on brain energy metabolism in migraine studied by in vivo 31-phosphorus NNMR spectroscopy. Neurology 1989;39:538-541.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.